Literature DB >> 3418088

5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?

M Campieri1, P Gionchetti, A Belluzzi, C Brignola, G M Tabanelli, M Miglioli, L Barbara.   

Abstract

Thirty-nine patients with documented active distal proctitis (less than 20 cm) received either 5-aminosalicylic acid (5-ASA) enemas (2 g in 100 ml) or suppositories 1 g b.i.d., in a controlled study. Twenty patients received enemas, while 19 patients received suppositories, for 30 days. No difference could be observed in terms of efficacy; however, it was the patients' opinion that treatment with suppositories was easier than that with enemas (p less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3418088     DOI: 10.1097/00004836-198808000-00012

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  11 in total

Review 1.  New steroids and new salicylates in inflammatory bowel disease: a critical appraisal.

Authors:  M Campieri
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

2.  Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial.

Authors:  M Campieri; P Gionchetti; A Belluzzi; C Brignola; M Tampieri; P Iannone; G Brunetti; M Miglioli; L Barbara
Journal:  Int J Colorectal Dis       Date:  1990-05       Impact factor: 2.571

3.  Evidence-based clinical practice guidelines for inflammatory bowel disease.

Authors:  Katsuyoshi Matsuoka; Taku Kobayashi; Fumiaki Ueno; Toshiyuki Matsui; Fumihito Hirai; Nagamu Inoue; Jun Kato; Kenji Kobayashi; Kiyonori Kobayashi; Kazutaka Koganei; Reiko Kunisaki; Satoshi Motoya; Masakazu Nagahori; Hiroshi Nakase; Fumio Omata; Masayuki Saruta; Toshiaki Watanabe; Toshiaki Tanaka; Takanori Kanai; Yoshinori Noguchi; Ken-Ichi Takahashi; Kenji Watanabe; Toshifumi Hibi; Yasuo Suzuki; Mamoru Watanabe; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2018-02-10       Impact factor: 7.527

4.  Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

Authors:  Javier P Gisbert; Fernando Gomollón; José Maté; José María Pajares
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

Review 5.  Current treatment of ulcerative colitis.

Authors:  Johannes Meier; Andreas Sturm
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

6.  Ulcerative proctitis.

Authors:  Charles B Whitlow
Journal:  Clin Colon Rectal Surg       Date:  2004-02

Review 7.  Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.

Authors:  Nielsen Q Fernandez-Becker; Alan C Moss
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Comparative tolerability of therapies for ulcerative colitis.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 9.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

10.  Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.

Authors:  M De Vos; H Verdievel; R Schoonjans; M Praet; M Bogaert; F Barbier
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.